District of Columbia Clinical Trials

Recruiting studies in District of Columbia

• A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
  NCT07128199PHASE3Taiho Oncology, Inc.Lung CancerWashington D.C., DC
• Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
  NCT07661056PHASE3Biohaven Therapeutics Ltd.Graves DiseaseWashington D.C., DC
• The Mechanistic Biology of Primary Immunodeficiency Disorders
  NCT03394053National Institute of Allergy and Infectious Diseases (NIAID)Primary Immunodeficiency DisordersWashington D.C., DC
• Genome Transplant Dynamics
  NCT02423070National Heart, Lung, and Blood Institute (NHLBI)Thoracic Organ TransplantationWashington D.C., DC
• A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
  NCT07310420PHASE1TerSera Therapeutics LLCAdvanced Breast CancerWashington D.C., DC
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654PHASE3Gilead SciencesTriple Negative Breast CancerWashington D.C., DC
• A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
  NCT07335588PHASE3LEO PharmaLichen SclerosusWashington D.C., DC
• Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
  NCT00001373National Human Genome Research Institute (NHGRI)Familial Mediterranean Fever (FMF)Washington D.C., DC
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967PHASE3Bristol-Myers SquibbPlaque PsoriasisWashington D.C., DC
• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
  NCT04302025PHASE2Genentech, Inc.Non-small Cell Lung CancerWashington D.C., DC
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  NCT01143454National Heart, Lung, and Blood Institute (NHLBI)Metabolic DiseaseWashington D.C., DC
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596PHASE2, PHASE3Mirati Therapeutics Inc.Advanced Non-Small Cell Lung CancerWashington D.C., DC

See all 805 recruiting trials →

Clinical trials by District of Columbia metro

• Washington DC

Popular conditions in District of Columbia

• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Colorectal Cancer
• Obesity
• Type 2 Diabetes
• Depression
• Alzheimer Disease
• Heart Failure
• Multiple Sclerosis
• Rheumatoid Arthritis
• Asthma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Frequently asked questions

How do I find clinical trials in District of Columbia?

Corterve aggregates actively recruiting clinical trials with sites in District of Columbia from the public ClinicalTrials.gov registry. Browse the studies on this page or take an assessment to find trials you may qualify for.

Are clinical trials in District of Columbia free to join?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

What kinds of clinical trials are available in District of Columbia?

District of Columbia research sites run studies across many areas including oncology, neurology, cardiology, and metabolic health. This page is general information and not medical advice; confirm any specific trial with your healthcare provider.